Review article| Volume 87, ISSUE 3, P319-330, March 2013

Download started.


Contraception technology: past, present and future


      Steady progress in contraception research has been achieved over the past 50 years. Hormonal and nonhormonal modern contraceptives have improved women's lives by reducing different health conditions that contributed to considerable morbidity. However, the contraceptives available today are not suitable to all users, and the need to expand contraceptive choices still exists. Novel products such as new implants, contraceptive vaginal rings, transdermal patches and newer combinations of oral contraceptives have recently been introduced in family planning programs, and hormonal contraception is widely used for spacing and limiting births. Concerns over the adverse effects of hormonal contraceptives have led to research and development of new combinations with improved metabolic profile. Recent developments include use of natural compounds such as estradiol and estradiol valerate with the hope to decrease thrombotic risk, in combination with newer progestins derived from the progesterone structure or from spirolactone, in order to avoid the androgenic effects. Progesterone antagonists and progesterone receptor modulators are highly effective in blocking ovulation and preventing follicular rupture and are undergoing investigations in the form of oral pills and in semi-long-acting delivery systems. Future developments also include the combination of a contraceptive with an antiretroviral agent for dual contraception and protection against sexually transmitted diseases, to be used before intercourse or on demand, as well as for continuous use in dual-protection rings. Although clinical trials of male contraception have reflected promising results, limited involvement of industry in that area of research has decreased the likelihood of having a male method available in the current decade. Development of nonhormonal methods is still at an early stage of research, with the identification of specific targets within the reproductive system in ovaries and testes, as well as interactions between spermatozoa and ova. It is hoped that the introduction of new methods with additional health benefits would help women and couples with unmet needs to obtain access to a wider range of contraceptives with improved acceptability.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Townsend J.W.
        • Sitruk-Ware R.
        • Williams K.
        • Askew I.
        • Brill K.
        New strategies for providing hormonal contraception in developing countries.
        Contraception. 2011; 83: 405-409
        • Giudice L.C.
        • Sitruk-Ware R.
        • Bremner W.J.
        • Hillard P.
        Scientific vision workshop on reproduction, workshop white paper.
        Eunice Kennedy Shriver National Institute of Child Health and Human Development, January 25–26, Bethesda, Maryland. 2011
        • United Nations (UN)
        World contraceptive use 2007 [wall chart]. UN Department of Economic and Social Affairs, Population Division, New York2008 (Available at:)
        • Population Reference Bureau Staff
        Transitions in world population.
        Popul Bull. 2004; : 1-43
      1. World population data sheet of the Population Reference Bureau. Population Reference Bureau, Washington, DC2004: 1-17
        • Daulaire N.
        • Leidl P.
        • Mackin L.
        • Murpy C.
        • Stark L.
        Promises to keep: the toll of unintended pregnancies on women's lives in the developing world. Global Health Council, Washington, DC2002
        • Speidel J.J.
        • Harper C.C.
        • Shields W.C.
        The potential of long-acting reversible contraception to decrease unintended pregnancy.
        Contraception. 2008; 78: 197-200
        • Finer L.B.
        • Henshaw S.K.
        Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.
        Perspect Sex Reprod Health. 2006; 38: 90-96
        • Finer L.B.
        • Kost K.
        Unintended pregnancy rates at the state level.
        Perspect Sex Reprod Health. 2011; 43: 78-87
        • Tsui A.O.
        • McDonald-Mosley R.
        • Burke A.E.
        Family planning and the burden of unintended pregnancies.
        Epidemiol Rev. 2010; 32: 152-174
        • World Health Organization (WHO)
        Unsafe abortion. Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2000. WHO, Geneva2004 (Available at:)
        • Frost J.J.
        • Darroch J.E.
        Factors associated with contraceptive choice and inconsistent method use, United States, 2004.
        Perspect Sex Reprod Health. 2008; 40: 94-104
        • Frost J.J.
        • Darroch J.E.
        • Remez L.
        Improving contraceptive use in the United States.
        Issues Brief (Alan Guttmacher Inst). 2008; : 1-8
        • Chandra A.
        • Martinez G.M.
        • Mosher W.D.
        • Abma J.C.
        • Jones J.
        Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth.
        Natl Cent Health Stat. 2005; 23: 95
        • Kost K.
        • Singh S.
        • Vaughan B.
        • Trussell J.
        • Bankole A.
        Estimates of contraceptive failure from the 2002 National Survey of Family Growth.
        Contraception. 2008; 77: 10-21
        • Sitruk-Ware R.
        Contraception: an international perspective.
        Contraception. 2006; 73: 215-222
        • Johansson E.D.
        The return of the pharmaceutical industry to the market of contraception.
        Steroids. 2000; 65: 709-711
        • Mishell Jr., D.R.
        Oral contraception: past, present, and future perspectives.
        Int J Fertil. 1991; 36: 7-18
        • Sitruk-Ware R.
        New progestagens for contraceptive use.
        Hum Reprod Update. 2006; 12: 169-178
        • Lidegaard Ø.
        • Løkkegaard E.
        • Svendsen A.L.
        • Agger C.
        Hormonal contraception and risk of venous thromboembolism: national follow-up study.
        BMJ. 2009; 339: b2890
        • Parke S.
        • Junge W.
        • Mellinger U.
        • Duijkers I.
        • Klipping C.
        Oral comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters.
        Hum Reprod. 2008; 23: i77-i78
        • Ågren U.M.
        • Anttila M.
        • Mäenpää-Liukko K.
        • et al.
        Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.
        Eur J Contracept Reprod Health Care. 2011; 16: 444-457
        • Chabbert-Buffet N.
        • Christin-Maitre S.
        • Ochsenbein E.
        • Thomas J.L.
        Synergistic effect of 17-βestradiol and nomegestrol acetate used in a new monophasic oral contraceptive.
        in: Paper presented at the 8th Congress of the European Society of Gynecology, Rome, 10 to 13 September2009
        • Visser M.
        • Coelingh-Bennink H.
        Estetrol: a new estrogen in the pill?.
        Eur J Contracept Reprod Health Care. 2008; 13 (abstract): 17
        • Chabbert-Buffet N.
        • Meduri G.
        • Bouchard P.
        • Spitz I.M.
        Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications.
        Hum Reprod Update. 2005; 11: 293-307
        • Brenner R.M.
        • Slayden O.D.
        Progesterone receptor antagonists and the endometrial antiproliferative effect.
        Semin Reprod Med. 2005; 23: 74-81
        • Chabbert-Buffet N.
        • Pintiaux-Kairis A.
        • Bouchard P.
        Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.
        J Clin Endocrinol Metab. 2007; 92: 358-368
        • Glasier A.F.
        • Cameron S.T.
        • Fine P.M.
        • et al.
        Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
        Lancet. 2010; 375: 555-562
        • Brache V.
        • Sitruk-Ware R.
        • Williams A.
        • et al.
        Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.
        Contraception. 2012; 85: 480-488
        • Alvarez-Sanchez F.
        • Brache V.
        • Jackanicz T.
        • Faundes A.
        Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control, and lipid profiles.
        Contraception. 1992; 46: 387-398
        • Timmer C.J.
        • Mulders T.M.
        Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
        Clin Pharmacokinet. 2000; 39: 233-242
        • Roumen F.J.
        • Apter D.
        • Mulders T.M.
        • Dieben T.O.
        Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyloestradiol.
        Hum Reprod. 2001; 16: 469-475
        • Ahrendt H.J.
        • Nisand I.
        • Bastianelli C.
        • et al.
        Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg of drospirenone.
        Contraception. 2006; 74: 451-457
        • Sivin I.
        • Diaz S.
        • Croxatto H.B.
        • et al.
        Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.
        Contraception. 1997; 55: 225-232
        • Massai R.
        • Miranda P.
        • Valdes P.
        • et al.
        Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women.
        Contraception. 1999; 60: 9-14
        • Diaz S.
        • Miranda P.
        • Brandeis A.
        • Cardenas H.
        • Croxatto H.B.
        Mechanism of action of progesterone as contraceptive for lactating women. Annals New York Academy of Sciences. Part II.
        Contracept Steril. 1991; 626: 11-21
        • Archer D.F.
        • Cullins V.
        • Creasy G.W.
        • Fisher A.C.
        The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.
        Contraception. 2004; 69: 189-195
        • Wan G.J.
        • Barnowski C.E.
        • Ambegaonkar B.M.
        • Bolge S.C.
        • McDonnell D.D.
        Treatment satisfaction with a transdermal contraceptive patch or oral contraceptives.
        Contraception. 2007; 75: 281-284
        • Sitruk-Ware R.
        • Plu-Bureau G.
        • Menard J.
        • et al.
        Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study.
        J Clin Endocrinol Metab. 2007; 92: 2074-2079
        • De Lignieres B.
        • Basdevant A.
        • Thomas G.
        • et al.
        Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
        J Clin Endocrinol Metab. 1986; 62: 536-541
        • Mashchak C.A.
        • Lobo R.A.
        • Dozono-Takano R.
        • et al.
        Comparison of pharmacodynamic properties of various estrogen formulations.
        Am J Obstet Gynecol. 1982; 144: 511-518
        • Scarabin P.Y.
        • Oger E.
        • Plu-Bureau G.
        Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
        Lancet. 2003; 362: 428-432
        • Rad M.
        • Kluft C.
        • Ménard J.
        • et al.
        Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
        Am J Obstet Gynecol. 2006; 195: 72-77
        • Heger-Mahn D.
        • Warlimont C.
        • Faustmann T.
        • Gerlinger C.
        • Klipping C.
        Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers.
        Eur J Contracept Reprod Health Care. 2004; 9: 173-181
        • Jensen J.T.
        The future of contraception: innovations in contraceptive agents: tomorrow's hormonal contraceptive agents and their clinical implications.
        Am J Obstet Gynecol. 2011; 205: S21-S25
        • Archer D.F.
        • Stanczyk F.Z.
        • Rubin A.
        • Foegh M.
        Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
        Contraception. 2012; 85: 595-601
        • Sitruk-Ware R.
        • Small M.
        • Kumar N.
        • Tsong Y.Y.
        • Sundaram K.
        • Jackanicz T.
        Nestorone: clinical applications for contraception and HRT.
        Steroids. 2003; 68: 907-913
        • Fraser I.
        • Weisberg E.
        • Kumar N.
        • et al.
        An initial pharmacokinetic study with Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive.
        Contraception. 2007; 76: 432-438
        • Nallasamy S.
        • Kim J.
        • Sitruk-Ware R.
        • Bagchi M.K.
        • Bagchi I.C.
        Ulipristal blocks ovulation by inhibiting progesterone Receptor-dependent pathways intrinsic to the ovary.
        Reprod Sci. 2012; ([in press])
        • Brache V.
        • Croxatto H.
        • Sitruk-Ware R.
        • et al.
        Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for “dual protection” emergency contraception.
        Contraception. 2007; 76: 11-16
        • Thonneau P.F.
        • Almont T.
        Contraceptive efficacy of intrauterine devices.
        Am J Obstet Gynecol. 2008; 198: 248-253
        • Backman T.
        • Rauramo R.
        • Huhtala S.
        • Koskenvou M.
        Pregnancy during the use of levonorgestrel intrauterine system.
        Am J Obstet Gynecol. 2004; 190: 50-54
        • Fraser I.S.
        Hysterectomy, endometrial destruction and the levonorgestrel intrauterine system are all effective therapies for heavy menstrual bleeding; satisfaction rates are highest after hysterectomy.
        Evid Based Med. 2011; 16: 55-56
        • Heikinheimo O.
        • Gemzell-Danielsson K.
        Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS).
        Acta Obstet Gynecol Scand. 2012; 91: 3-9
        • Gemzell-Danielsson K.
        • Schellschmidt I.
        • Apter D.
        A randomized, Phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
        Fertil Steril. 2012; 97: 616-622
      2. A study of a levonorgestrel-releasing intrauterine system for long-term, reversible contraception. Available on Last accessed on 10/31/11.

      3. An explorative trial to explore the safety, acceptability and vaginal bleeding pattern of three etonogestrel-releasing medicated intrauterine systems. Available on Last accessed on 10/31/11.

        • Brenner R.M.
        • Slayden O.D.
        • Nath A.
        • Tsong Y.Y.
        • Sitruk-Ware R.
        Intrauterine administration of CDB-2914 (ulipristal) suppresses the endometrium of rhesus macaques.
        Contraception. 2010; 81: 336-342
        • Brenner R.M.
        • Slayden O.D.
        • Nayak N.R.
        • Baird D.T.
        • Critchley H.O.
        A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists.
        Steroids. 2003; 68: 1033-1039
        • Fuhrmann U.
        • Hess-Stumpp H.
        • Cleve A.
        • et al.
        Synthesis and biologic activity of a novel, highly potent progesterone receptor antagonist.
        J Med Chem. 2000; 43: 5010-5016
        • Heikinheimo O.
        • Vani S.
        • Carpén O.
        • et al.
        Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study.
        Hum Reprod. 2007; 22: 2515-2522
        • International Collaborative Post-Marketing Surveillance of Norplant
        Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health.
        Contraception. 2001; 63: 167-186
        • Graesslin O.
        • Korver T.
        The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience.
        Eur J Contracept Reprod Health Care. 2008; 13: 4-12
        • Massai M.R.
        • Díaz S.
        • Quinteros E.
        • et al.
        Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women.
        Contraception. 2001; 64: 369-376
        • Sivin I.
        • Croxatto H.
        • Bahamondes L.
        • et al.
        Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women.
        Contraception. 2004; 69: 137-144
        • Coutinho E.M.
        • de Souza J.C.
        • Athayde C.
        • et al.
        Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant.
        Contraception. 1996; 53: 121-125
        • Pitts S.A.
        • Feldman H.A.
        • Dorale A.
        • Gordon C.M.
        Bone mineral density, fracture, and vitamin D in adolescents and young women using depot medroxyprogesterone acetate.
        J Pediatr Adolesc Gynecol. 2012; 25: 23-26
        • Draper B.H.
        • Morroni C.
        • Hoffman M.
        • Smit J.
        • Beksinska M.
        • Hapgood J.
        • et al.
        Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
        Cochrane Database Syst Rev. 2006; 19: CD005214
        • Dinger J.C.
        • Heinemann L.A.
        • Kühl-Habich D.
        The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
        Contraception. 2007; 75: 344-354
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • Løkkegaard E.
        Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10.
        BMJ. 2012; 344: e2990
        • Goebelsmann U.
        • Mashchak C.A.
        • Mishell Jr., D.R.
        Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
        Am J Obstet Gynecol. 1985; 151: 868-877
        • Fraser I.S.
        • McCarron G.
        Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.
        Aust N Z J ObstetGynaecol. 1991; 31: 66-70
        • Jensen J.T.
        • Parke S.
        • Mellinger U.
        • Machlitt A.
        • Fraser I.S.
        Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.
        Obstet Gynecol. 2011; 117: 777-787
        • Kaunitz A.M.
        • Meredith S.
        • Inki P.
        • Kubba A.
        • Sanchez-Ramos L.
        Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis.
        Obstet Gynecol. 2009; 113: 1104-1116
        • Davis A.R.
        • Westhoff C.
        • O'Connell K.
        • Gallagher N.
        Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial.
        Obstet Gynecol. 2005; 106: 97-104
        • Aslam N.
        • Blunt S.
        • Latthe P.
        Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents.
        J ObstetGynaecol. 2010; 30: 489-491
        • Shabaan M.M.
        • Zakherah M.S.
        • El-Nashar S.A.
        • Sayed G.H.
        Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial.
        Contraception. 2011; 83: 48-54
        • Arowojolu A.O.
        • Gallo M.F.
        • Lopez L.M.
        • Grimes D.A.
        • Garner S.E.
        Combined oral contraceptive pills for treatment of acne.
        Cochrane Database Syst Rev. 2009; : CD004425
        • Freeman E.W.
        • Kroll R.
        • Rapkin A.
        • et al.
        Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
        J Womens Health Gend Based Med. 2001; 10: 561-569
        • Michaelsson K.
        • Baron J.A.
        • Farahmand B.Y.
        • Persson I.
        • Ljunghall S.
        Oral contraceptive use and risk of hip fracture: a case–control study.
        Lancet. 1999; 353: 1481-1484
        • Westhoff C.
        • Britton J.A.
        • Gammon M.D.
        • Wright T.
        • Kelsey J.L.
        Oral contraceptive and benign ovarian tumors.
        Am J Epidemiol. 2000; 152: 242-246
        • Maguire K.
        • Westhoff C.
        The state of hormonal contraception today: established and emerging noncontraceptive health benefit.
        Am J Obstet Gynecol. 2011; 205: S4-S8
        • Wiehle R.
        • Lantvit D.
        • Yamada T.
        • Christov K.
        Aa progesterone receptorptosis.
        Cancer Prev Res (Phila). 2011; 4: 414-424
        • Liu L.
        • Zhao L.
        • She H.
        • et al.
        Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo.
        Endocrinology. 2010; 151: 5782-5794
        • Hussain R.
        • El-Etr M.
        • Gaci O.
        • et al.
        Progesterone and nestorone facilitate axon remyelination: a role for progesterone receptors.
        Endocrinology. 2011; 152: 3820-3831
        • Barnhart K.T.
        • Rosenberg M.J.
        • MacKay H.T.
        • et al.
        Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
        Obstet Gynecol. 2007; 110: 577-586
        • Mauck C.K.
        • Freziers R.G.
        • Walsh T.L.
        • Peacock K.
        • Schwartz J.L.
        • Callahan M.M.
        Noncomparative contraceptive efficacy of cellulose sulfate gel.
        Obstet Gynecol. 2008; 111: 739-746
        • Burke A.E.
        • Barnhart K.
        • Jensen J.T.
        • et al.
        Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial.
        Obstet Gynecol. 2010; 116: 1265-1273
        • Hillier S.L.
        • Moench T.
        • Shattock R.
        • Black R.
        • Reichelderfer P.
        • Veronese F.
        In vitro and in vivo: the story of nonoxynol 9.
        J Acquir Immune Defic Syndr. 2005; 39: 1-8
        • Schwartz J.L.
        • Ballagh S.A.
        • Creinin M.D.
        • et al.
        SILCS diaphragm: postcoital testing of a new single-size contraceptive device.
        Contraception. 2008 Sep; 78: 237-244
        • Jesam C.
        • Salvatierra A.M.
        • Schwartz J.L.
        • Croxatto H.B.
        Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception.
        Hum Reprod. 2010; 25: 368-373
        • Pall M.
        • Fridén B.E.
        • Brännström M.
        Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.
        Hum Reprod. 2001; 16: 1323-1328
        • Han S.J.
        • Vaccari S.
        • Nedachi T.
        • et al.
        Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation.
        EMBO J. 2006; 25: 5716-5725
        • Hanna C.B.
        • Yao S.
        • Patta M.C.
        • Jensen J.T.
        • Wu X.
        WEE2 is an oocyte-specific meiosis inhibitor in Rhesus macaque monkeys.
        Biol Reprod. 2010; 82: 1190-1197
        • Peluffo M.C.
        • Barrett S.L.
        • Stouffer R.L.
        • Hennebold J.D.
        • Zelinski M.B.
        Cumulus–oocyte complexes from small antral follicles during the early follicular phase of menstrual cycles in rhesus monkeys yield oocytes that reinitiate meiosis and fertilize in vitro.
        Biol Reprod. 2010; 83: 525-532
        • Fan H.Y.
        • Liu Z.
        • Shimada M.
        • et al.
        MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility.
        Science. 2009; 324: 938-941
        • Wu X.
        • Wang P.
        • Brown C.A.
        • Zilinski C.A.
        • Matzuk M.M.
        • et al.
        Zygote arrest 1 (Zar1) is an evolutionarily conserved gene expressed in vertebrate ovaries.
        Biol Reprod. 2003; 69: 861-867
        • Hugon-Rodin J.
        • Chabbert-Buffet N.
        • Bouchard P.
        The future of women's contraception: stakes and modalities.
        Ann N Y Acad Sci. 2010; 1205: 230-239
        • Anderson R.A.
        • Baird D.T.
        Male contraception.
        Endocr Rev. 2002; 23: 735-762
        • Wang C.
        • Swerdloff R.S.
        Hormonal approaches to male contraception.
        Curr Opin Urol. 2010; 20: 520-524
        • Kumar N.
        • Didolkar A.K.
        • Monder C.
        • Bardin C.W.
        • Sundaram K.
        The biological activity of 7a-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone.
        Endocrinology. 1992; 130: 3677-3683
        • Ilani N.
        • Roth M.Y.
        • Amory J.K.
        • et al.
        New combination of testosterone and nestorone transdermal gels for male hormonal contraception.
        J Clin Endocrinol Metab. 2012; (Jul 12 [Epub ahead of print])
        • Mahabadi V.
        • Amory J.K.
        • Swerdloff R.S.
        • et al.
        Combined transdermal testosterone gel and the progestin Nestorone suppresses serum gonadotropins in men.
        J Clin Endocrinol Metab. 2009; 94: 2313-2320
        • Mommers E.
        • Kersemaekers W.M.
        • Elliesen J.
        • et al.
        Male hormonal contraception: a double-blind, placebo-controlled study.
        J Clin Endocrinol Metab. 2008; 93: 2572-2580
        • Nieschlag E.
        • Zitzmann M.
        • Kamischke A.
        Use of progestins in male contraception.
        Steroids. 2003; 68: 965-972
        • Cheng C.Y.
        • Lie P.P.
        • Wong E.W.
        • Mruk D.D.
        • Silvestrini B.
        Adjudin disrupts spermatogenesis via the action of some unlikely partners: Eps8, Arp2/3 complex, drebrin E, PAR6 and 14-3-3.
        Spermatogenesis. 2011; 1: 291-297